SCHEMBL75765

SCHEMBL75765

O=C(O)COCC#Cc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.51
MMP2 P08253 2/20 0.45
MMP12 P39900 2/20 0.45
EGLN1 Q9GZT9 4/20 0.45
FFAR1 O14842 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
SLC1A5 Q15758 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446075 0.91 FFAR1 (0.50) PTGDR2MMP2MMP12FFAR1ALDH1A1
SCHEMBL10362542 0.82 LMNA (0.49) PTGDR2MMP2MMP12EGLN1MEN1
SCHEMBL17555048 0.79 LMNA (0.43) PTGDR2MMP2MMP12EGLN1MEN1
SCHEMBL6447328 0.78 FFAR1 (0.48) PTGDR2MMP2MMP12FFAR1ALDH1A1
SCHEMBL25199212 0.77 PTGDR2 (0.46) PTGDR2MMP2MMP12EGLN1FFAR1
SCHEMBL7420788 0.75 MMP2 (0.40) MMP2MMP12FFAR1ALDH1A1KDM4E
SCHEMBL12468934 0.75 CYP1A2 (0.46) PTGDR2EGLN1MEN1KMT2ALMNA
SCHEMBL75802 0.75 CYP2D6 (0.45) PTGDR2EGLN1MEN1KMT2ALMNA
SCHEMBL11111469 0.74 ALDH1A1 (0.41) PTGDR2EGLN1MEN1KMT2ALMNA
SCHEMBL11111466 0.74 ALDH1A1 (0.41) PTGDR2EGLN1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-7166746-B2 N-bisaryl- and n-aryl-cycloakylidenyl-αhydroxy-and α-alkoxy acid amides SYNGENTA CROP PROTECTION, INC. (US) 2007-01-23 US disclosed
US-20050245607-A1 N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides SYNGENTA CROP PROTECTION, INC. 2005-11-03 US disclosed
EP-1534664-A1 N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES Syngenta Participations AG (CH) 2005-06-01 EP disclosed
WO-2004011417-A1 N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245607-A1 N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides CBR3, CBR1, AKR1C3 PTGDR2 2076/4885MMP2 2284/4885MMP12 2568/4885
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D PTGDR2 231/4885MMP2 469/4885MMP12 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.